Page last updated: 2024-09-04

cyc 202 and ginsenosides

cyc 202 has been researched along with ginsenosides in 1 studies

Compound Research Comparison

Studies (cyc 202)	Trials (cyc 202)	Recent Studies (post-2010) (cyc 202)	Studies (ginsenosides)	Trials (ginsenosides)	Recent Studies (post-2010) (ginsenosides)
979	7	393	4,821	61	3,179

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Feng, J; Hou, J; Li, M; Li, X; Quan, Q; Zhang, B	1

Other Studies

1 other study(ies) available for cyc 202 and ginsenosides

Article	Year
Ginsenoside Rg1 reduces β‑amyloid levels by inhibiting CDΚ5‑induced PPARγ phosphorylation in a neuron model of Alzheimer's disease. Molecular medicine reports, 2020, Volume: 22, Issue:4 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cells, Cultured; Cyclin-Dependent Kinase 5; Female; Gene Expression Regulation; Ginsenosides; Hippocampus; Male; Models, Biological; Phosphorylation; PPAR gamma; Primary Cell Culture; Rats; Roscovitine; Signal Transduction	2020

Article

Year

Ginsenoside Rg1 reduces β‑amyloid levels by inhibiting CDΚ5‑induced PPARγ phosphorylation in a neuron model of Alzheimer's disease.

Molecular medicine reports, 2020, Volume: 22, Issue:4

Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cells, Cultured; Cyclin-Dependent Kinase 5; Female; Gene Expression Regulation; Ginsenosides; Hippocampus; Male; Models, Biological; Phosphorylation; PPAR gamma; Primary Cell Culture; Rats; Roscovitine; Signal Transduction

2020